Patients with low (compared with elevated) or lower than median baseline levels of S100A8/9, S100A12, and CRP had at least double the likelihood of achieving JIA-ACR ID or JIA-ACR100 after abatacept initiation. This evidence concerns the gene CRP and juvenile idiopathic arthritis.